Fibrolamellar carcinoma (FLC) is driven by a unique fusion protein called DNAJB1::PRKACA (DP). This fusion is responsible for the growth of the tumor cells, and without it, the tumor dies. Unfortunately, targeting this fusion with drugs has proven extremely difficult, because the fusion’s active site is almost identical to that of normal protein kinase A …
Fibrolamellar carcinoma (FLC) is a rare, aggressive liver cancer affecting adolescents and young adults. Nearly all cases contain the same genetic abnormality — a fusion protein called DNAJ‑PKAc. This study provides clear evidence that the fusion protein fundamentally reshapes both the metabolism of the cancer and immune behavior. Importantly, this rewiring reveals a specific therapeutic …
This in-depth description of a Phase 1 clinical trial initiated in April 2020 provides strong initial evidence for the safety and efficacy of a therapeutic vaccine against fibrolamellar carcinoma (FLC). The vaccine was given in combination with two immune checkpoint inhibitors (ICIs) already approved for use against many cancers. Published in the prestigious journal Nature …